Gallant Pet Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 8

  • Investments
  • 1

Gallant Pet General Information

Description

Developer of a pet health technology platform designed to deliver regenerative stem cell therapies for improved veterinary care. The company's platform offers standardized stem cell banking, allogeneic treatments, and controlled field trials of off-the-shelf stem cell therapies grounded in scalable science, enabling veterinarians in primary care settings to provide improved treatment options and better health outcomes for companion animals.

Contact Information

Website
www.gallant.com
Formerly Known As
AngelList Talent
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Corporate Office
  • 10865 Road to the Cure
  • Suite 101
  • San Diego, CA 92121
  • United States
+1 (855)
Primary Industry
Other Commercial Services
Parent Company
Corporate Office
  • 10865 Road to the Cure
  • Suite 101
  • San Diego, CA 92121
  • United States
+1 (855)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gallant Pet Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gallant Pet‘s full profile, request access.

Request a free trial

Gallant Pet Patents

Gallant Pet Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022380747-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
CA-3235721-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
EP-4426816-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
EP-4426816-A4 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021
US-20250019662-A1 Primed uterine-derived regenerative cell compositions and uses thereof Pending 04-Nov-2021 C12N5/0682
To view Gallant Pet’s complete patent history, request access »

Gallant Pet Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gallant Pet Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gallant Pet‘s full profile, request access.

Request a free trial

Gallant Pet Acquisitions (1)

Gallant Pet’s most recent deal was a Merger/Acquisition with Cook Regentec (veterinary division). The deal was made on 24-Oct-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cook Regentec (veterinary division) 24-Oct-2019 Merger/Acquisition Other Healthcare Services
To view Gallant Pet’s complete acquisitions history, request access »

Gallant Pet FAQs

  • When was Gallant Pet founded?

    Gallant Pet was founded in 2018.

  • Where is Gallant Pet headquartered?

    Gallant Pet is headquartered in San Diego, CA.

  • What is the size of Gallant Pet?

    Gallant Pet has 50 total employees.

  • What industry is Gallant Pet in?

    Gallant Pet’s primary industry is Other Commercial Services.

  • Is Gallant Pet a private or public company?

    Gallant Pet is a Private company.

  • What is Gallant Pet’s current revenue?

    The current revenue for Gallant Pet is .

  • How much funding has Gallant Pet raised over time?

    Gallant Pet has raised $60.4M.

  • Who are Gallant Pet’s investors?

    2Future Holdings, 77 Ventures, Alpha Edison, Alumni Ventures, and BOLD Capital Partners are 5 of 25 investors who have invested in Gallant Pet.

  • When was Gallant Pet acquired?

    Gallant Pet was acquired on 17-Nov-2026.

  • Who acquired Gallant Pet?

    Gallant Pet was acquired by Dechra Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process